Home/Products /imatinib-400-mg-tablet

IMAFIX 400 Tablet: Imatinib 400 mg - Targeted Oncology Therapy

Name: IMAFIX 400: Imatinib 400 mg Tablet | Top Tyrosine Kinase Inhibitor for CML & GIST Franchise
Brand: Imafix 400 Tablet
Rating: 4.8 (150 reviews)

Tyrosine Kinase Inhibition: How Imatinib Revolutionized CML Treatment

Primary Indications: Ph+ CML (Chronic Myeloid Leukemia)

Secondary Indications: GIST, Ph+ ALL, and other PDGFR/c-KIT Driven Disorders

The Advantage: Long-Term Oral Treatment & High Patient Compliance

Secure Your Monopoly: IMAFIX 400 PCD Pharma Franchise with Premium Support

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Imatinib 400 mg tablet strip for CML treatment

Graphic illustrating BCR-ABL kinase inhibition mechanism

Target therapy tablet for Gastrointestinal Stromal Tumors (GIST)

Oncology PCD Pharma franchise marketing visual for Imatinib

Imafix 400 Tablet

Composition : Imatinib 400 mg Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

IMAFIX 400 Tablet (Imatinib 400 mg) is a highly specialized, oral, targeted cancer therapy classified as a Tyrosine Kinase Inhibitor (TKI). It is globally recognized as the revolutionary first-line treatment for Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML).

Mechanism and Impact:

Imatinib works by selectively targeting and blocking the activity of the abnormal BCR-ABL fusion protein, a mutated tyrosine kinase that drives the uncontrolled proliferation of CML cells. By blocking this specific "switch," Imatinib effectively halts the progression of the disease, allowing many CML patients to achieve long-term molecular and cytogenetic remission.

Key Therapeutic Uses:

Chronic Myeloid Leukemia (CML): The cornerstone therapy for newly diagnosed Ph+ CML in the chronic phase.
Gastrointestinal Stromal Tumors (GIST): Used to treat unresectable or metastatic GIST that expresses the c-Kit (CD117) positive receptor.
Acute Lymphoblastic Leukemia (ALL): Part of combination regimens for Ph+ ALL.

Due to the chronic nature of CML and the necessity for extended, often indefinite, patient dosing, Imatinib 400 mg maintains a remarkably stable and high-volume demand in the pharmaceutical market.

We offer an unparalleled PCD Pharma Franchise opportunity for IMAFIX 400. This specialization allows franchise partners to target institutional sales (oncology centers, large hospitals) and secure long-term revenue streams through a product of massive clinical importance and proven efficacy.

About the Product

Mechanism and Impact:

Key Therapeutic Uses:

Chronic Myeloid Leukemia (CML): The cornerstone therapy for newly diagnosed Ph+ CML in the chronic phase.
Gastrointestinal Stromal Tumors (GIST): Used to treat unresectable or metastatic GIST that expresses the c-Kit (CD117) positive receptor.
Acute Lymphoblastic Leukemia (ALL): Part of combination regimens for Ph+ ALL.

May cause nausea, vomiting, fatigue, low blood counts, hair loss, and bladder irritation. Rarely, neurotoxicity, kidney toxicity, or severe infections may occur.

Soft tissue and bone sarcomas Lymphomas Testicular cancer Other solid tumors as per oncologist’s guidance

Administer only under strict medical supervision in a hospital or oncology setting. Blood counts, liver, kidney, and bladder function should be regularly monitored. Adequate hydration and protective agents may be required to prevent bladder toxicity. Report any neurological symptoms, unusual bleeding, or infections promptly.

Store below 25°C, protected from light. Keep out of reach of children. Use immediately after reconstitution as per medical instructions.